Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab Real World Effectiveness in Migraine
NCT05284019Phase 4Terminated
- Sponsor
- Lundbeck
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of eptinezumab in migraine, sponsored by Lundbeck. Started Mar 2022; status: terminated.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05284019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284019.